Clinical trials for Liver and bile duct cancer

141 currently recruiting clinical trials

Early Access Liver and bile duct cancer
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Jazz Pharmaceuticals
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Liver and bile duct cancer #NCT07221253 #2025-523085-24-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
AstraZeneca
Phase 3 Liver and bile duct cancer #NCT06921785 #2024-518210-81-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required liver status
Unhealthy
Required Child-Pugh scores
A
Required BCLC stage (Barcelona Clinic Liver Cancer)
B C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
6 recruiting sites
AstraZeneca
Phase 3 Liver and bile duct cancer #NCT06467357 #2023-508057-19-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy Antibody Drug Conjugates (ADC)
8 recruiting sites
AstraZeneca
Phase 3 Liver and bile duct cancer #NCT05615818 #2023-508100-38-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
35 recruiting sites
UNICANCER
Phase 3 Liver and bile duct cancer #NCT06282575 #2023-508219-21-00
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
11 recruiting sites
Jazz Pharmaceuticals
Phase 3 Liver and bile duct cancer #NCT04803994 #2024-512953-26-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Required liver status
Unhealthy
Required Child-Pugh scores
A B
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
10 recruiting sites
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Liver and bile duct cancer #NCT05948475
Required histologic sub types
Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
TransThera Sciences (Nanjing), Inc.
Phase 3 Liver and bile duct cancer #NCT05078047
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER